All conditions

COPD

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

3853
Trials on record
319
Recruiting now
8
Australian sites
18
Phase 3 trials
18
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for COPD →

Get alerts when COPD trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding COPD

COPD stands for Chronic Obstructive Pulmonary Disease. It is a long-term lung condition that makes it harder to breathe over time. The airways and air sacs inside the lungs become damaged and partly blocked, which means air cannot move in and out as freely as it should. Common symptoms include a persistent cough, shortness of breath during everyday activities, and increased mucus or phlegm. COPD is not something that comes on suddenly — it develops gradually, usually over many years.

In Australia, COPD is very common. It affects an estimated one in thirteen Australians over the age of 40, and it is one of the leading causes of illness and hospitalisation in this country. Smoking is the most common cause, but long-term exposure to dust, fumes, or air pollution can also contribute. Some people are surprised to learn they have COPD, as the early symptoms can be easy to overlook or put down to simply "getting older."

While COPD cannot currently be cured, there are several treatments that doctors commonly use to help manage symptoms and slow the progression of the condition. These typically include medications delivered through inhalers, pulmonary rehabilitation programs that involve supervised exercise and education, and practical support to help people stay as active as possible in their daily lives. For people who smoke, stopping smoking is widely recognised as one of the most important steps in managing the condition. A GP or specialist can talk through what the right combination of support might look like for each individual person.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for COPD in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for COPD

18 medicines listed on the PBS for COPD. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 18 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Aclidinium Bretaris Genuair Chronic obstructive pulmonary disease (COPD) AU$42.7 Restricted benefit
Aclidinium + formoterol Brimica Genuair Chronic obstructive pulmonary disease (COPD) AU$61.58 Streamlined authority
beclometasone + formoterol + glycopyrronium Trimbow Chronic obstructive pulmonary disease (COPD) AU$57.05 Streamlined authority
Budesonide + formoterol Symbicort Rapihaler 200/6, DuoResp Spiromax, Symbicort TURBUHALER 400/12 Chronic obstructive pulmonary disease (COPD) AU$22.06 Streamlined authority
budesonide + glycopyrronium + formoterol Breztri Aerosphere Chronic obstructive pulmonary disease (COPD) AU$60.93 Streamlined authority
fluticasone furoate + umeclidinium + vilanterol Trelegy Ellipta 100/62.5/25 Chronic obstructive pulmonary disease (COPD) AU$66.86 Streamlined authority
fluticasone furoate + vilanterol Breo Ellipta 100/25 Chronic obstructive pulmonary disease (COPD) AU$39.79 Streamlined authority
fluticasone propionate + salmeterol Seretide Accuhaler 500/50, Seretide MDI 250/25 Chronic obstructive pulmonary disease (COPD) AU$36.65 Streamlined authority
Glycopyrronium seebri breezhaler Chronic obstructive pulmonary disease (COPD) AU$42.7 Restricted benefit
Indacaterol Onbrez Chronic obstructive pulmonary disease (COPD) AU$42.7 Restricted benefit
indacaterol + glycopyrronium ultibro breezhaler 110/50 Chronic obstructive pulmonary disease (COPD) AU$68.39 Streamlined authority
Ipratropium Atrovent, Atrovent Adult Chronic obstructive pulmonary disease (COPD) AU$6.41 Restricted benefit
Salbutamol Ventolin Nebules, Salbutamol (as sulfate) (Accord, UK), Salbutamol Cipla Chronic obstructive pulmonary disease (COPD) AU$2.98 Restricted benefit
Tiotropium Spiriva, Braltus, Tiotropium Lupin Chronic obstructive pulmonary disease (COPD) AU$24.28 Restricted benefit
tiotropium + olodaterol Spiolto Respimat Chronic obstructive pulmonary disease (COPD) AU$114.54 Streamlined authority
Tiotropium + olodaterol Spiolto Respimat Chronic obstructive pulmonary disease (COPD) AU$57.27 Streamlined authority
Umeclidinium Incruse Ellipta Chronic obstructive pulmonary disease (COPD) AU$42.7 Restricted benefit
umeclidinium + vilanterol Anoro Ellipta 62.5/25 Chronic obstructive pulmonary disease (COPD) AU$68.38 Streamlined authority
Tiotropium Spiriva Respimat Bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease AU$28.82 Restricted benefit

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for COPD currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for COPD.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for COPD by country. Australia is highlighted.

Showing the top 10 of 62 countries with trial sites.

Clinical trials for COPD

Showing 329 of 329 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00297102 · AstraZeneca Phase 3 · 11 countries Completed
Completed Phase 3 Est. completion 1 July 2008
🇦🇺 AU🇦🇹 AT🇧🇷 BR🇫🇷 FR🇩🇪 DE🇭🇺 HU🇳🇿 NZ🇷🇴 RO +3 more

**Who might be able to join this trial:** - You have been diagnosed with COPD (chronic obstructive pulmonary disease) and have had at least one flare-up (worsening of symptoms) in the past year - Your breathing test results show a specific pattern of airflow limitation, with a ratio of two measurements (FEV1/FVC) at 70...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00615459 · Novartis Phase 3 · 7 countries Completed
Completed Phase 3 Est. completion 1 December 2008
🇦🇺 AU🇩🇪 DE🇳🇱 NL🇳🇿 NZ🇵🇱 PL🇿🇦 ZA🇪🇸 ES

Who might be able to join this trial: - You are a man or woman aged 40 or older who is willing to sign a consent form before any study activities begin - You have been diagnosed with moderate to severe chronic obstructive pulmonary disease (COPD), a long-term lung condition that makes it hard to breathe - You have a sm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00792805 · Novartis Pharmaceuticals Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 1 February 2010
🇦🇺 AU🇨🇳 CN🇮🇳 IN

Who might be able to join this trial: - You are 40 years of age or older - You have been diagnosed with moderate to severe chronic obstructive pulmonary disease (COPD), a long-term lung condition that makes it hard to breathe - You have a smoking history of at least 10 "pack years" (for example, smoking one pack per da...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01040130 · Boehringer Ingelheim Phase 3 · 5 countries Completed
Completed Phase 3 Est. completion 1 April 2011
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇫🇷 FR🇩🇪 DE

Who might be able to join this trial: - You have agreed to take part by signing a consent form before the study begins. - You have been diagnosed with chronic obstructive pulmonary disease (COPD) and your breathing test results meet certain specific measurements (confirm with trial site). - You are between 40 and 75 ye...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01513460 · Novartis Pharmaceuticals Phase 3 · 2 countries Completed
Completed Phase 3 Est. completion 1 December 2013
🇦🇺 AU🇳🇿 NZ

**Who might be able to join this trial:** - You have been diagnosed with moderate to severe COPD (classified as Stage II or Stage III under standard medical guidelines) - You are a current smoker or ex-smoker with a smoking history of at least 10 "pack years" (for example, smoking one pack a day for 10 years, or two pa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01636076 · Novartis Pharmaceuticals Phase 2 · 18 countries Completed
Completed Phase 2 Est. completion 1 September 2013
🇦🇺 AU🇧🇪 BE🇧🇬 BG🇩🇰 DK🇫🇮 FI🇩🇪 DE🇬🇷 GR Hong Kong +10 more

**Who might be able to join this trial:** - You have been diagnosed with moderate to very severe COPD (a lung condition that makes it hard to breathe), based on recognised international guidelines. - Breathing tests done after using a bronchodilator (an inhaler that opens the airways) show your lung function is below c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01854645 · Pearl Therapeutics, Inc. Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 1 February 2015
🇦🇺 AU🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - You are between 40 and 80 years old - You have been diagnosed with COPD (a long-term lung condition) based on recognised medical guidelines - You are a current or former smoker with at least a 10 pack-year smoking history (for example, smoking one pack a day for 10 years, or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02261727 · The George Institute Phase 4 · 1 country Completed
Completed Phase 4 Est. completion 14 May 2018
🇦🇺 AU

**Who might be able to join this trial:** - You are a current or past smoker (with a significant smoking history of more than 10 "pack years") or have had long-term exposure to smoke from burning wood, coal, or other solid fuels - You are between 40 and 80 years old - You have been diagnosed with COPD (a chronic lung...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT02465567 · Pearl Therapeutics, Inc. Phase 3 · 26 countries Completed
Completed Phase 3 Est. completion 26 July 2019
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇿 CZ +18 more

**Who might be able to join this trial:** - Women who cannot become pregnant, are at least 2 years past menopause, or who test negative for pregnancy at the first visit and agree to use reliable birth control throughout the study. - People who have been formally diagnosed with COPD (a chronic lung condition) based on r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04710576 · Syndax Pharmaceuticals Phase 2 · 16 countries Recruiting
Recruiting Phase 2 Est. completion 7 April 2023
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇱 IL🇮🇹 IT +8 more

**Who might be able to join this trial:** - People aged 2 years or older at the time of signing the consent form. - People who have received an allogeneic stem cell transplant (a transplant using stem cells from a donor) and have active chronic graft-versus-host disease (cGVHD) — a condition where the donor cells atta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05878769 · Hoffmann-La Roche Phase 3 · 40 countries Recruiting
Recruiting Phase 3 Est. completion 1 July 2034
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +32 more

**Who might be able to join this trial:** - People who have completed the full 52-week treatment period in one of the two related earlier studies (called GB43311 or GB44332) **Who may not be able to join:** - People who withdrew their consent or left the earlier study early before finishing it - People whose study med...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06496620 · Uniquity One (UNI) Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇦🇺 AU🇨🇦 CA🇳🇿 NZ🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who are between 40 and 75 years of age - People who have been diagnosed with COPD for at least 12 months before the screening visit, and who have elevated levels of a certain type of white blood cell (eosinophils) in their blood at screening - People whose breathing t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06585774 · Incyte Corporation Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 28 September 2027
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇹 IT +5 more

Who might be able to join this trial: - People who are 12 years of age or older at the time of giving consent to participate. - People who have been newly diagnosed with moderate or severe chronic graft-versus-host disease (cGVHD) — a condition that can occur after a stem cell transplant — that requires treatment throu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06878261 · AstraZeneca Phase 3 · 22 countries Recruiting
Recruiting Phase 3 Est. completion 13 March 2029
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇬 BG🇨🇴 CO🇩🇰 DK🇫🇷 FR🇬🇷 GR +14 more

**Who might be able to join this trial:** - People aged 40 to 80 years old - People who have been diagnosed with COPD for at least 1 year - People whose lung function test results fall within a specific range, showing moderate-to-severe airflow limitation (confirm exact values with trial site) - People who have been t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06961214 · GlaxoSmithKline Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 21 August 2029
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇿 CZ🇩🇪 DE🇬🇷 GR🇮🇱 IL +7 more

**Who might be able to join this trial:** - People aged between 40 and 80 years old at the time of signing the consent form - People with a higher-than-normal level of a type of white blood cell called eosinophils in their blood - People with a confirmed diagnosis of COPD (a chronic lung condition) for at least 1 year...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06986070 · SMSbiotech Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇦🇺 AU

**Who might be able to join this trial:** - People aged 39 to 69 years old (inclusive) - Women who are not pregnant or breastfeeding, and who are either unable to have children, or who are willing to use an acceptable form of contraception from the screening stage until 30 days after the last dose of the study treatme...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07082738 · AstraZeneca Phase 2 · 24 countries Recruiting
Recruiting Phase 2 Est. completion 5 November 2027
🇦🇷 AR🇦🇺 AU🇧🇬 BG🇨🇦 CA🇨🇱 CL🇨🇳 CN🇩🇰 DK🇩🇪 DE +16 more

Who might be able to join this trial: - People who are 40 years of age or older at the time of signing the consent form. - People who have had a confirmed diagnosis of COPD (chronic obstructive pulmonary disease) for at least 12 months before joining. - People whose lung function test results meet specific measurements...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07134686 · Assistance Publique Hopitaux De Marseille Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 November 2028

**Who might be able to join this trial:** - You are 18 years old or older (male or female) - You have been diagnosed with asthma - You have been diagnosed with chronic rhinosinusitis with nasal polyps (a condition where growths develop inside the nose and sinuses) - Your asthma and/or sinus condition is not well contro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00128973 · National Institute of Allergy and Infectious Diseases (NIAID) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** *As a patient:* - People aged 2 years or older who have no active infections may be seen in person at the clinic; however, samples sent in for diagnostic purposes may be accepted at any age. - People who have signs of immune system problems, such as frequent or unusual infecti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00307281 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2030
🇺🇸 US

"Who might be able to join this trial: - People who have been diagnosed with COPD (Chronic Obstructive Pulmonary Disease), confirmed through at least one of the following: a doctor's clinical assessment, breathing/lung function test results, or chest imaging results (such as an X-ray or CT scan). Who may not be able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00576069 · Gelb, Arthur F., M.D. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who are currently non-smokers and have smoked less than 10 pack-years in total throughout their lifetime - People who have asthma that is stable and being treated with medication - People between the ages of 12 and 95 years old - People whose lung function test results, ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01177618 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - You developed COPD at a younger age, specifically before age 53 - Your breathing test results show severe COPD, meaning your lungs are working at less than 40% of the expected level for someone your age and size - A doctor has officially diagnosed you with COPD Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01225913 · Gelb, Arthur F., M.D. Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who are currently non-smokers with a limited smoking history (fewer than 10 pack-years total) - People who have asthma that is stable and being treated with medication - People between 10 and 80 years of age - People whose lung function test results, taken after using a st...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02592291 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People who are 12 years of age or older. - People who have been diagnosed with a long-term and complex condition, such as Spina Bifida, Spinal Cord Injury, Cerebral Palsy, Traumatic Brain Injury, or a similar condition. - People who live independently in the community, rather tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02755974 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇬🇧 GB

Who might be able to join this trial: - People whose lung function test results show a specific pattern of reduced airflow (a ratio of two breathing measurements — FEV1 and FVC — that is less than 0.70), which can indicate a breathing condition such as COPD (confirm with trial site) - People who are willing and able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02777879 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2030
🇺🇸 US

Who might be able to join this trial: - People who have smoked more than 20 pack-years (a measure of long-term smoking history) and have a breathing test result showing reduced airflow, but not severely reduced (this is called early-stage COPD, classified as GOLD 1 or 2). - Smokers with normal breathing test results ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02779478 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have experienced lung-related symptoms such as cough, tiredness, general feeling of being unwell, fever, unexplained weight loss, shortness of breath, coughing up blood, or chest discomfort. - People who have had an abnormal chest X-ray or CT scan within the past...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02803242 · COPD Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇺🇸 US

"Who might be able to join this trial: - People aged 18 years or older who have been diagnosed with COPD (a lung disease) - People aged 18 years or older who currently smoke or have smoked in the past - People aged 18 years or older who have a family member with a respiratory (breathing-related) disease - People aged 1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02815683 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇳🇱 NL

Who might be able to join this trial: - People who are scheduled to have a bronchoscopic lung volume reduction procedure using one-way valves (a procedure where small valves are placed in the airways through a flexible camera scope to reduce the size of damaged areas of the lung). Who may not be able to join: - There...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03014609 · University Hospital, Grenoble Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇫🇷 FR

**Who might be able to join this trial:** *For people with stable COPD:* - Men or women between 18 and 85 years old - People with a confirmed COPD diagnosis, shown either by a specific breathing test result (FEV1/FVC below 70%) or by an existing COPD diagnosis - People who have given written consent to participate fre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03033251 · Unity Health Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 April 2025
🇨🇦 CA

Who might be able to join this trial: - People who have a flare-up of COPD (chronic obstructive pulmonary disease) causing a buildup of carbon dioxide in the blood, shown by specific blood gas test results (confirm with trial site) - People whose breathing rate is 20 breaths per minute or more during the flare-up - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03105843 · Dr. Diane Lougheed Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2026
🇨🇦 CA

**Who might be able to join this trial:** - Adults between 18 and 65 years old who have been diagnosed with cough-variant asthma (CVA), meaning they have had a persistent cough for 8 weeks or more as their main symptom, tested positive on a specific breathing test called a methacholine challenge, and have a history of...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03263130 · Gelb, Arthur F., M.D. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with both asthma and COPD (a condition sometimes called "asthma-COPD overlap") - People who have emphysema (a type of lung damage) and a smoking history of more than 15 pack years (a measure of how much someone has smoked over their lifetime) - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03318406 · Uptake Medical Technology, Inc. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇦🇹 AT🇩🇪 DE🇨🇭 CH

**Who might be able to join this trial:** - People who have a type of emphysema called "heterogeneous emphysema," confirmed by a detailed CT scan showing that the disease is unevenly distributed across at least one area of the lung that would be treated. - People who are 18 years of age or older. - People who are will...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03331302 · University of Virginia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2020
🇺🇸 US

**Who might be able to join this trial:** - You must have been diagnosed with COPD (a lung condition that makes it hard to breathe). - You must be at your usual, stable level of health on the day of the scan — not in the middle of a flare-up or worsening of symptoms. - You must be classified into a COPD category accord...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03450603 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with Chronic Obstructive Pulmonary Disease (COPD), a long-term lung condition that makes it hard to breathe. - People who are 40 years of age or older. Who may not be able to join: - People who are unable to complete a breathing test cal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03799354 · Istituti Clinici Scientifici Maugeri SpA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇮🇹 IT

Who might be able to join this trial: - People with a COPD diagnosis that meets standard medical guidelines, where specific breathing test results show the airways are significantly narrowed (confirm with trial site) - People whose COPD is currently stable and not in an active flare-up Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03807310 · Maastricht University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇳🇱 NL

**For COPD Patients:** Who might be able to join this trial: - You have been diagnosed with moderate to very severe COPD (known as GOLD stage II, III, or IV) - Your condition is currently stable and not in a period of sudden worsening Who may not be able to join: - You are under 18 years old - You have an allergy or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03877653 · Curonix LLC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇺🇸 US

Who might be able to join this trial: - People who are over 18 years of age - People who have had ongoing, function-limiting knee pain from osteoarthritis for at least three months, with a pain score above 6 out of 10 on a specific pain scale, whether or not they have had previous knee surgeries - People who have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03890224 · Clinact Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2024
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with COPD at a severe stage (classified as GOLD C or D) with lung function below a certain level (FEV1 less than 65%) - People who have recently had an episode of serious breathing difficulties with too much carbon dioxide in the blood (a condi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04018729 · Hospital de Clinicas de Porto Alegre Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 17 August 2020
🇧🇷 BR

Who might be able to join this trial: - People diagnosed with severe emphysema where the damage is unevenly spread across the lungs, affecting at least 10% of the total lung tissue or 25% of the target area - People where the difference in lung damage between the treated area and the rest of the lung on the same side i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04062292 · Hacettepe University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
Turkey (Türkiye)

**For People with Obstructive Lung Disease:** Who might be able to join this trial: - People who have been diagnosed with an obstructive lung disease - People who have not had a sudden worsening of symptoms or an infection in the past week - People who are between 18 and 65 years old - People who are willing to take p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04157049 · Alpha-1 Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 June 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with Alpha-1 Antitrypsin Deficiency (a genetic condition that can affect the lungs and liver), including specific genetic types such as PiZZ, PiZNull, and PiSZ, among others. - People who carry the gene associated with Alpha-1 Antitrypsin Deficiency...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04179981 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with moderate-to-severe obstructive sleep apnea (a condition where breathing repeatedly stops during sleep), confirmed by an overnight sleep study showing 20 or more breathing interruptions per hour - People who also have moderate-to-severe COP...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04200079 · Dr. Juan Pablo de Torres Tajes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇦 CA

**Who might be able to join this trial:** - People between the ages of 40 and 85 years old - People who have smoked at least 10 pack-years (roughly the equivalent of one pack per day for 10 years) in their lifetime - People who currently smoke or who used to smoke - People who have been diagnosed with COPD based on a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04220463 · Rennes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 November 2025
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older who have been admitted to a medical intensive care unit - People with a Glasgow score of 15 (meaning they are fully alert and responsive) - People experiencing sudden breathing difficulties related to COPD (a lung condition) and/or who have obesity, de...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04252781 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 January 2025
🇫🇷 FR

**Who might be able to join this trial:** **Initial screening phase (Phase I):** - People who are over 35 years old - People who have smoked more than 20 pack-years (a measure of long-term smoking history — confirm with trial site if unsure how this is calculated) - People who are currently smoking, or who stopped smo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04427826 · University Hospital, Grenoble Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 8 June 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older - People who currently smoke or used to smoke, with a smoking history of at least 10 pack-years (a measure of how much someone has smoked over their lifetime) - People who have been diagnosed with COPD (a lung condition) based on recognised medical gu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04722835 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People between 40 and 75 years old. - People who have a smoking history of at least 20 pack-years (a measure of how much a person has smoked over their lifetime — confirm with trial site if unsure how this applies). - People who have not been diagnosed with COPD or asthma. -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04791891 · Laval University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇦 CA

Who might be able to join this trial: - People who are at least 18 years old - People who have access to the internet - People who are fluent in English or French - People who have had low back pain in the past 4 weeks that was bad enough to limit their usual activities or change their daily routine for more than one d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04801108 · Beth Israel Deaconess Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

Who might be able to join this trial: - People between 40 and 75 years of age. - People whose condition is stable and who are taking less than 10mg of prednisone (or a similar steroid medication) per day. - People who have not smoked for at least 4 months before the screening visit and who are willing to remain non-smo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04849806 · RWTH Aachen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇪 DE

Who might be able to join this trial: - People who are 18 years of age or older - People who are able and willing to give their consent to take part in the study Who may not be able to join: - People who have atrial fibrillation (an irregular heartbeat condition) - People whose heart rate is fully controlled by a pace...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04860375 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇸🇪 SE

**Who might be able to join this trial:** - People aged 40 years or older, of any gender - People who are current smokers or ex-smokers with a significant smoking history (at least 10 "pack-years," which is roughly the equivalent of smoking one pack a day for 10 years) - People who have previously been admitted to hosp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04890938 · McMaster University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇨🇦 CA

Who might be able to join this trial: - People who have had 2 or more flare-ups of their chronic obstructive pulmonary disease (COPD) in the past 12 months, have a certain breathing test result or emphysema visible on a scan, and have a smoking history of at least 10 pack-years (a measure that combines how much and how...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05008081 · Wim Janssens Not Applicable · 11 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇸🇮 SI🇪🇸 ES +3 more

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with COPD (a lung condition) by a doctor, either based on their medical history or a breathing test result - People who are currently in hospital with a suspected flare-up (sudden worsening) of their COPD - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05033990 · University of Massachusetts, Worcester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - **Healthy control group (40 people):** People aged 30–55 with no history of smoking, vaping, or cannabis use (fewer than 100 cigarettes in their lifetime), and whose breathing test results are within the normal range, and who score below 10 on a standard airway symptom quest...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05053061 · Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
Turkey (Türkiye)

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with COPD (a lung condition that makes it hard to breathe) - You have never taken part in a pulmonary rehabilitation programme before (a programme designed to help people with lung conditions through exercise and education)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05061368 · University of Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇨🇦 CA

Who might be able to join this trial: **For people with COPD:** - A person must have a COPD diagnosis confirmed by a breathing test showing a specific airflow ratio (FEV1/FVC) below the normal lower limit after using a bronchodilator - A person's lung function (FEV1) must be above 30% of what is expected for someone o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05147688 · The Foundation for Orthopaedics and Regenerative Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
Antigua and Barbuda

**Who might be able to join this trial:** - People who have been diagnosed with a lung disease - People who are willing and able to understand and sign a written consent form **Who may not be able to join:** - People who currently have an active infection - People who currently have active cancer - People whose multip...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05163600 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇭 CH

**For Healthy Participants** Who might be able to join this trial: - People who are 18 years of age or older - People who are in generally good health Who may not be able to join: - People with a physical or intellectual condition that would make it difficult to understand the study or follow its procedures - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05196698 · University Hospital, Rouen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 August 2026
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with COPD (a lung condition), as defined by recognized medical guidelines - You have been admitted to hospital due to a flare-up (worsening) of your COPD - You have severe breathing problems, meaning your blood oxygen levels are very low — either alre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05204888 · Temple University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign and date a consent form agreeing to take part - People who are willing to follow all study procedures and are available for the full duration of the study - People aged 30 years or older (any gender) - People with breathing test result...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05227547 · Centre Hospitalier Intercommunal Creteil Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 October 2030
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older - You are scheduled to have surgery to remove part or all of a lung (such as a lobe, segment, or the whole lung) because of cancer or suspected cancer - You are willing to take part in the study and give your agreement to participate - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05236062 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 September 2026
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have recently been diagnosed with a complication called GVHD (a condition where donated cells react against the body after a transplant) and have just started taking steroid medication for it for the first time since your transplant - You re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05257681 · Beth Israel Deaconess Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 May 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged between 40 and 75 years old - People whose condition is stable and who are taking less than 10mg of prednisone (or a similar steroid medication) per day - People who have not smoked for at least 4 months before the screening visit and who are willing to remain smo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05265299 · Johns Hopkins University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 40 years of age or older - People who used to smoke but no longer do - People who have a smoking history of at least 10 pack-years (roughly equal to smoking one pack per day for 10 years, or an equivalent amount over a different period) - People whose breathing...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05270525 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Je... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 40 to 80 years who have smoked at least 10 pack-years (for example, one pack per day for 10 years) and have been diagnosed with COPD based on established medical guidelines. - People whose breathing test results show a specific level of airflow limitation — measu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05297279 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - People who are 40 years of age or older - People who have been diagnosed with COPD (a lung disease) by a doctor - People whose COPD falls into a moderate-to-very-severe range, based on specific breathing test results (a breathing test showing certain airflow and lung capacity mea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05306743 · Observational and Pragmatic Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - The participants in this trial are **Primary Care Teams** (groups of healthcare staff who work together to care for a group of patients), not individual patients. - The Primary Care Team must be able to operate as a single, separate unit with little risk of the study's metho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05337072 · Universitair Ziekenhuis Brussel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇧🇪 BE

Who might be able to join this trial: - Women who are planning to have IVF or ICSI fertility treatment at Brussels IVF (UZ Brussel) - Women who are scheduled to have a diagnostic hysteroscopy (a camera examination of the inside of the womb) as part of preparing for their fertility treatment Who may not be able to join...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05399056 · Baystate Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 40 years or older - People who have recently received treatment for a COPD flare-up (worsening of symptoms), either in a hospital or through outpatient care - People who have been referred to a pulmonary rehabilitation (lung exercise and education) program - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05437198 · Centre Hospitalier Intercommunal Creteil Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

Who might be able to join this trial: **For people with COPD (a long-term lung condition):** - People who have been diagnosed with chronic obstructive pulmonary disease (COPD) - People aged 18 or older **For people without COPD:** - People who have not been diagnosed with COPD - People aged between 18 and 30, or betw...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05572632 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are willing to sign and date a consent form agreeing to take part in the study - People who are willing to take part in the COPD Wellness program - People between 40 and 90 years old - People who speak English or Spanish - People who have been diagnosed with COPD by a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05598983 · Life Detection Technologies Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who have been officially diagnosed with COPD (a long-term lung condition) - People who have had one or more flare-ups (worsening of symptoms requiring extra treatment) in the past year - People who are 18 years of age or older - People who are willing to use health mon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05660460 · Hvidovre University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇩🇰 DK

Who might be able to join this trial: - Adults aged 18 years or older - People who can speak and understand Danish or English well enough to give informed consent Who may not be able to join: - People who do not have a Danish civil registration number, as without this number the trial site cannot arrange free access t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05671198 · Isala Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇳🇱 NL

**Who might be able to join this trial:** - You are in hospital mainly because of a serious sudden worsening of COPD (Chronic Obstructive Pulmonary Disease). - You have been diagnosed with COPD according to recognised medical guidelines (GOLD 2018 definition). - A breathing test done within the last 5 years showed that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05685628 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 April 2027
🇫🇷 FR

**Who might be able to join this trial:** - People over 18 years old who have a wound with an unpleasant smell that causes noticeable discomfort (rated more than 4 out of 10 by the patient) - People whose wound is expected to take more than 14 days to heal, based on a doctor's assessment - People who are covered by the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05701982 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 40 or older, of any gender - People who have been diagnosed with COPD, defined as having smoked more than 10 pack-years and either having reduced lung function on breathing tests or showing signs of emphysema on a chest CT scan (confirm with trial site for virtua...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05703919 · Central Denmark Region Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 May 2027
🇩🇰 DK

Who might be able to join this trial: - People who are over 40 years of age - People where an EMT or Paramedic suspects they are having a flare-up of COPD (a lung condition) - People where COPD has been confirmed as a suspected diagnosis Who may not be able to join: - People whose breathing difficulties are caused by...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05708443 · Istituti Clinici Scientifici Maugeri SpA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇮🇹 IT

**Who might be able to join this trial:** - People diagnosed with moderate-to-severe COPD (classified as GOLD class 2 or 3) - People whose lung function test results (specifically how much air can be forcefully exhaled in one second) fall between 30% and 70% of what would normally be expected for someone of their age a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05717192 · IHF GmbH - Institut für Herzinfarktforschung Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 April 2026
🇩🇪 DE

Who might be able to join this trial: - People aged between 40 and 75 years old - People who have given written consent to take part - People diagnosed with severe emphysema that mainly affects the upper parts of both lungs, at an advanced stage (classified as GOLD stage 3 or 4) - People whose lung scans (taken within...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05720780 · Istituti Clinici Scientifici Maugeri SpA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with COPD (a long-term lung condition), confirmed by a specific breathing test showing reduced airflow that does not improve with an inhaler - People who have ongoing breathing difficulties due to low oxygen levels in the blood, even when resting an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05724745 · Commissariat A L'energie Atomique Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇫🇷 FR

**Who might be able to join this trial:** *All participants must meet these general criteria:* - You must be able to understand what the study involves and what it is trying to achieve - You must be able to lie still inside an MRI scanner on your back for the full length of the scans - You must be able to give written...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05730088 · Necmettin Erbakan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2023
Turkey (Türkiye)

**Who might be able to join this trial:** - People who have been diagnosed with stage 4 (the most severe stage, also called Group D) COPD, based on GOLD guidelines - People who are 18 years of age or older - People who have access to a computer, tablet, or phone with video capability - People who have an internet conne...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05743582 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇬🇧 GB

**Who might be able to join this trial:** *For people with COPD:* - People with COPD between the ages of 18 and 77, with a mild to moderate-severe disease stage (GOLD Stage 1, 2, or 3), who are already having a bronchoscopy (a camera procedure into the airways) for a medical reason - People with COPD between the ages...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05772013 · Dr Ian B Wilkinson Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2028
🇬🇧 GB

**Who might be able to join this trial:** - People who are able and willing to give their consent to take part in the trial. - People who have been diagnosed with COPD and have been taking azithromycin (an antibiotic) regularly for at least 3 months to help prevent COPD flare-ups. - People who have a self-reported smo...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05785026 · KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2028
🇧🇪 BE

**Who might be able to join this trial:** - Adults aged 18 years or older - People who can speak, read, and write Dutch or English - People with normal lung function test results — specifically, a FEV1/FVC ratio above 0.70 and FEV1 at or above 80% of the expected value (for certain parts of the trial only — confirm wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05799664 · Hangzhou Broncus Medical Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 40 and 75 years old - People who have been diagnosed with COPD, with breathing test results showing a specific level of airflow limitation and reduced lung function (confirm specific test values with the trial site) - People whose COPD symptoms score at a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05825261 · Maastricht University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 years or older - People who currently have breathing symptoms such as shortness of breath, cough, or mucus/phlegm production - People who have had breathing tests (spirometry) showing a type of airflow blockage that does not fully reverse with an inhaler, and/o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05829083 · Larissa University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇬🇷 GR

Who might be able to join this trial: - People experiencing a sudden worsening of their COPD symptoms that goes beyond their normal day-to-day changes, and that has required a change in their medication. - People whose blood tests show a mild-to-moderate build-up of carbon dioxide in the blood, with specific measuremen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05919511 · Incyte Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 October 2027
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older at the time of signing the consent form - People who received a stem cell transplant from a donor between 90 and 180 days before enrolling in the trial - People who are able to understand and are willing to give their informed consent to pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05922202 · Azienda Ospedaliero-Universitaria di Modena Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2025
🇮🇹 IT

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with COPD (a lung condition) for at least 1 year - Your COPD has been stable, meaning you have not had a sudden worsening of symptoms in the last 30 days and have not been hospitalised for any reason in the last 3 months - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05922761 · Dana-Farber Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** **Cohort A** (diagnosed with Bronchiolitis Obliterans Syndrome, or BOS, after a stem cell/bone marrow transplant): - A person must have a confirmed diagnosis of BOS after a blood stem cell transplant, based on specific breathing test results that meet either the standard or "...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05938738 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who are 40 years of age or older - People who have read, understood, and signed a consent form agreeing to take part - People diagnosed with moderate-to-very-severe COPD (a specific lung function measurement below 60% of what is expected, and a symptom score of 10 or m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05939999 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2025
🇧🇷 BR

Who might be able to join this trial: - You have been diagnosed with moderate to very severe COPD (a serious lung condition), based on specific international guidelines from 2020 - Your COPD has been stable, meaning you have not had a flare-up or worsening of symptoms for at least 30 days - You are male - You are not o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05951777 · Hope Biosciences LLC Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged between 18 and 55 years old - People who have documented brain or nervous system damage caused by a closed head injury (a head injury that did not break the skull), where current standard treatments are unlikely to help further - People whose level of recovery fal...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05962164 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇦 CA

**Who might be able to join this trial:** - You are a non-smoker - You are over 40 years old - You have been diagnosed with moderate-to-severe COPD that has been stable (no flare-ups) for more than 6 weeks, confirmed by specific breathing test results (confirm with trial site) **Who may not be able to join:** - You ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05976919 · University of Leeds Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇬🇧 GB

Who might be able to join this trial: - People who have previously been diagnosed with an airways disease, according to European Respiratory Society guidelines. - People who have never smoked, or who used to smoke but no longer do. - People aged between 18 and 65 years old, male or female. - People who are able to give...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05996627 · Fred Hutchinson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been clinically diagnosed with chronic graft-versus-host disease (cGVHD) — a condition that can occur after a stem cell or bone marrow transplant — with at least one recognised sign or symptom of the condition (a formal NIH classification is not required) - I...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06018766 · Steven Hays, MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years old - People who received a double lung transplant at least 12 months before joining the study - People who have been diagnosed with a specific type of chronic lung transplant complication called CLAD-BOS, where breathing test results (measuring...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06068322 · Umeå University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇧🇪 BE🇸🇪 SE

Who might be able to join this trial: - People who are 60 years of age or older - People who are able to carry out everyday tasks on their own (such as dressing, eating, and moving around) - People with COPD who have noticeable symptoms (measured by specific breathing questionnaires) or who have not been regularly acti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06072690 · Lithuanian University of Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇱🇹 LT

Who might be able to join this trial: - People who are 40 years of age or older. - People who have smoked at least 10 pack-years (for example, one pack per day for 10 years, or two packs per day for 5 years). - People who have been recently diagnosed with chronic obstructive pulmonary disease (COPD), a lung condition t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06084117 · Franciscus Gasthuis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with chronic obstructive pulmonary disease (COPD), a long-term lung condition that makes breathing difficult - People who are currently experiencing a sudden worsening of their COPD where carbon dioxide has built up in the blood and the blood ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06110403 · University Hospital, Lille Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged 40 to 75 years old at the time of joining the trial - People who have a confirmed diagnosis of COPD, with breathing test results showing a specific level of airflow limitation and reduced lung function (confirm with trial site for exact test values) - People with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06114667 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are an adult who has been admitted to the emergency department with a flare-up of COPD (a lung condition that makes breathing difficult) - You are able to understand the study information and agree to take part - You are covered by social security (health insurance/social...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06148324 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a documented diagnosis of a complicated-mild, moderate, or severe traumatic brain injury (TBI), confirmed through records such as emergency services reports, hospital records, or doctor's notes, and who required a stay in an inpatient rehabilitation unit - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06152107 · Shanghai Chest Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People diagnosed with severe emphysema who have a certain number of treatable airway areas in one lung, as measured by a specialised CT scan - People who have not smoked for at least 2 months before joining, and who are willing to remain smoke-free...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06163131 · Aarhus University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 November 2026
🇩🇰 DK

Who might be able to join this trial: - People who have been chosen by their doctor to receive a treatment involving small one-way valves placed inside the airways (called endobronchial valves) - People who have signed a consent form agreeing to take part in the trial Who may not be able to join: - People who have a n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06163807 · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 June 2026
🇪🇸 ES

Who might be able to join this trial: **General asthma group:** - Adults aged 18 to 80 who have been diagnosed with asthma (with or without nasal polyps) of any severity level, based on standard diagnostic guidelines. - People who are already being followed up as part of the existing MEGA asthma study cohort. - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06169488 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇳🇴 NO

**Who might be able to join this trial:** - Men and women (who are not pregnant) between 20 and 65 years old who have had ongoing low back pain for at least one year - People who have already tried non-surgical treatments following standard guidelines — including self-management, exercise, and physical therapy — witho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06181357 · University Hospital, Limoges Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 June 2029
🇫🇷 FR

**Who might be able to join this trial:** - People who are able to give their informed consent and take part in the study - People aged between 35 and 80 years old at the time of signing the consent form - People who have emphysema (either evenly spread or unevenly spread across the lungs) confirmed on a CT scan taken...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06188065 · Northumbria Healthcare NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇬🇧 GB

Who might be able to join this trial: - People who have been admitted to hospital with a flare-up of COPD (a lung condition often caused by smoking) as their main diagnosis - People who have a smoking history of at least 10 pack years (this is a measure of how much someone has smoked over time — confirm with trial site...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06198309 · Li An Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with moderate-to-severe COPD (a serious lung condition), confirmed by specific breathing test results meeting GOLD Grade III or IV standards - People who are older than 40 years of age - People whose COPD has been stable for more than 4 weeks -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06201299 · Istanbul Medipol University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
Turkey (Türkiye)

Who might be able to join this trial: - People aged between 18 and 75 years old - People who have been diagnosed with COPD (a long-term lung condition) based on recognised international medical guidelines - People who experience breathlessness during physical activity - People whose condition has been stable, with no i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06201403 · Istanbul Medipol University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2026
Turkey (Türkiye)

**Who might be able to join this trial:** **For people with COPD:** - People who have been diagnosed with Group C or D COPD based on the GOLD staging system (a standard system doctors use to classify how severe COPD is) - People who have been taking the same COPD medications without any changes for at least the past 4...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06217276 · Istanbul Medipol University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2026
Turkey (Türkiye)

**Who might be able to join this trial:** **For people with COPD:** - People who have been diagnosed with Stage 2 or Stage 3 COPD, based on guidelines set by the American Thoracic Society and European Respiratory Society - People who have been taking the same medications without any changes for at least the past 4 wee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06233110 · Stefanie Sarantopoulos, MD, PhD. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form before any study-related screening takes place - People who are 18 years of age or older at the time of signing consent - People who have previously received a stem cell transplant (using bone marrow, blood stem...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06235502 · Aalborg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇩🇰 DK

Who might be able to join this trial: - Adults aged 18 years or older - People admitted to hospital for a worsening of COPD (Chronic Obstructive Pulmonary Disease) who already have a confirmed COPD diagnosis - People who live in Aalborg Municipality - People who are able to give their informed consent to participate -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06253013 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇦 CA

Who might be able to join this trial: - You were recently discharged from UHN hospital after a flare-up of COPD (a sudden worsening of symptoms), and have been referred to either a Virtual Pulmonary Rehabilitation program or Remote Clinical Monitoring at Toronto Grace Health Centre Who may not be able to join: - Your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06273072 · Johns Hopkins University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with asthma by a doctor and are currently taking regular asthma medication to manage it - People whose asthma is not well-controlled, meaning their asthma control test (ACT) score is below 20, or they have had at least one asthma flare-up in the pas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06275230 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are under 55 years old, of any gender - People who have COPD (a lung condition that makes it hard to breathe) and are already scheduled to have a bronchoscopic biopsy (a procedure where a small sample of lung tissue is taken using a thin, flexible tube passed through t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06283004 · Acibadem University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - People who have been diagnosed with COPD, classified in groups A, B, or E according to a standard medical assessment system called GOLD - People who are able to walk and move around on their own - People who do not have any health reasons that would prevent them from doing ex...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06286072 · Kirsehir Ahi Evran Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2024
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with COPD (a lung condition) for at least 1 year - People who have been hospitalised for at least 3 days - People who are willing to take part voluntarily Who may not be able to join: - People who are under 18 years old - People who are over 85 yea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06332885 · Pulmonx Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇯🇵 JP

**Who might be able to join this trial:** - Your doctor has decided you are a suitable candidate for a lung procedure using a device called the Zephyr Valve, following Japanese medical guidelines - You have completed a breathing/lung exercise rehabilitation programme within the last 6 months - You have not smoked for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06334575 · Maria Joyera Rodríguez Phase 4 · 4 countries Recruiting
Recruiting Phase 4 Est. completion 1 December 2027
🇩🇪 DE🇳🇱 NL🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People aged 40 or older (men and women) - People who have a history of smoking at least 10 pack-years (a measure of lifetime smoking amount — confirm with trial site if unsure) - People who stopped smoking at least 6 months ago - People whose breathing test results show a spe...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06335992 · Uppsala University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇸🇪 SE

Who might be able to join this trial: - People whose lung function test (a breathing test called FEV1) shows a result between 30% and 85% of the expected normal value, measured after using a reliever inhaler - People who are already receiving the best available standard treatment for their lung condition, following rec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06347536 · Guy's and St Thomas' NHS Foundation Trust Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇬🇧 GB

Who might be able to join this trial: - People who are 40 years of age or older - People who have been admitted to hospital for a flare-up of their COPD (chronic obstructive pulmonary disease) and have recently been discharged from hospital care, including from virtual ward support (the hospital stay must have lasted a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06349174 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 March 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with chronic obstructive pulmonary disease (COPD) using standard diagnostic guidelines - You are between 40 and 85 years old (inclusive) - Your body mass index (BMI) is 35 or below - Your lung function test results fall within a specific range showing mode...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06366113 · Michaël RACODON Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 January 2024
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with chronic obstructive pulmonary disease (COPD), a long-term lung condition that makes breathing difficult - People who are enrolled in a breathing and physical rehabilitation program at the Clinique de la Mitterie...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06376994 · JHSPH Center for Clinical Trials Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are 40 years of age or older - People who have been told by a doctor that they have COPD (a lung condition that makes it hard to breathe) - People whose breathing test results confirm a specific type of airway blockage, measured using a lung function test called sp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06377410 · National University of Malaysia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇲🇾 MY

**Who might be able to join this trial:** - People who have been diagnosed with stable COPD, based on the GOLD 2023 guidelines - People aged 40 years or older - People whose breathing test results show a specific pattern of airflow limitation (a post-bronchodilator FEV1/FVC ratio below 70% or below the lower limit of n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06392776 · Ottawa Hospital Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇦 CA

Who might be able to join this trial: - People who are 18 years old or older - People who are currently experiencing breathing or respiratory symptoms - People who complete a questionnaire called the UCAP-Q and receive a score showing at least a 6% chance of having asthma or COPD - People who have signed a written cons...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06401512 · Western Norway University of Applied Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇳🇴 NO

Who might be able to join this trial: - People who have been diagnosed with COPD (a lung condition) and are living at home - People whose lung function test results (a specific breathing measurement taken after using a puffer) fall below the normal range for their age and body size Who may not be able to join: - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06413524 · Taipei Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 April 2025
🇹🇼 TW

**Who might be able to join this trial:** - People aged 40 or older. - People who have been diagnosed with chronic obstructive pulmonary disease (COPD) — a long-term lung condition that makes it hard to breathe — based on internationally recognised guidelines. - People whose COPD is classified as more severe (based on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06473701 · Vejle Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇩🇰 DK

**Who might be able to join this trial:** - People who have severe or very severe COPD (classified as GOLD stage 3 or 4) - People who still experience significant breathlessness even after receiving the best available standard treatment - People whose breathlessness is rated at level 3 or higher on a standard scale cal...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06474039 · Mahidol University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇹🇭 TH

Who might be able to join this trial: - People who have been diagnosed with a specific stage of COPD (called GOLD B), meaning they have had no more than one flare-up (worsening of symptoms) in the year before joining the study - People with this stage of COPD who have previously been treated with one or more types of i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06480604 · The Archer-Daniels-Midland Company Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇮🇳 IN

**Who might be able to join this trial:** - You are a woman who has not yet reached menopause, aged between 18 and 50 years - You have a current vaginal yeast infection caused by Candida (confirmed by a lab test within 24–48 hours of your symptoms starting, and before any treatment was started) - You have had at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06491043 · Meribank Biotech Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - People aged 40 to 80 years old, of any sex or race - People who have been diagnosed with COPD according to established international guidelines - People whose breathing test results show a specific pattern of airflow limitation after using a bronchodilator (a lung-opening me...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06497816 · Hacettepe University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2027
Turkey (Türkiye)

**Who might be able to join this trial:** *For people with COPD:* - You are over 40 years old - You have been diagnosed with COPD and your condition is currently stable - You are able to follow instructions and participate in the tests required by the study - You do not have any heart, bone/joint, or nerve-related con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06509308 · Fondazione Don Carlo Gnocchi ETS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2023
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with COPD (a lung condition), confirmed by a breathing test called spirometry - People who are adults (18 years or older) - People who speak Italian - People who are able to complete the required tests involved in the study - People who have given t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06518473 · Mansoura University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2025
🇪🇬 EG

Who might be able to join this trial: - You are between 40 and 70 years old and have been diagnosed with COPD (a long-term lung condition that makes it hard to breathe) based on recognised 2024 guidelines Who may not be able to join: - You have a known allergy condition or allergic disease - You have another long-term...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06519474 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇹🇼 TW

Who might be able to join this trial: - People who are at least 20 years old - People who have been diagnosed with COPD and have not had an infection or sudden worsening of symptoms in the past four weeks - People who are able to participate in and complete the tests and measurements required by the study Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06523140 · Biosency Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - People over 18 years of age who have been diagnosed with COPD (a long-term lung condition) according to established medical guidelines, and whose lung function has been measured within the last 12 months while their condition was stable - People who have been admitted to hosp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06529185 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 December 2024
🇪🇬 EG

**Who might be able to join this trial:** - You are a male aged between 55 and 60 years old with a diagnosis of mild to moderate COPD (Grade I or Grade II) - You are in a stable condition, both physically and medically, at the time of joining the study - Your body weight is in a healthy range, with a Body Mass Index (B...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06533371 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are being seen regularly as an outpatient for a long-term lung condition called COPD (chronic obstructive pulmonary disease), your condition is currently stable, and a CT scan has shown a specific type of lung damage called emphysema (air sac destruction in certain patter...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06551441 · Rigshospitalet, Denmark Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇩🇰 DK

Who might be able to join this trial: - People aged 40 to 79 years (both men and women) - People who have been diagnosed with COPD at a mild to moderately severe level (known as GOLD stage I to III) - People with a breathlessness score ranging from none to quite severe on a standard scale (mMRC score of 0 to 3) - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06578156 · University of Miami Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who are able to give their informed consent to participate - People aged 18 years or older - People who have been diagnosed with COPD (chronic obstructive pulmonary disease) - People who are able to walk around without help from another person or a mobility aid - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06584786 · Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2024
🇹🇼 TW

**Who might be able to join this trial:** - People who have been diagnosed with COPD (Chronic Obstructive Pulmonary Disease) and are willing to take part in the study **Who may not be able to join:** - People who have not been diagnosed with COPD - People who are not willing to take part in the study **Important: Alw...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06595784 · Hellenic Thoracic Society Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇬🇷 GR

**Who might be able to join this trial:** - People who have been diagnosed with chronic obstructive pulmonary disease (COPD) and also have at least one heart or blood vessel condition, such as heart failure, a buildup of fatty deposits in the arteries, an irregular heartbeat (atrial fibrillation), or a serious heart va...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06597331 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇸🇪 SE

Who might be able to join this trial: - Adults aged 18 or older who have been admitted to a hospital ward for a flare-up (sudden worsening) of COPD (chronic obstructive pulmonary disease) - People enrolled in the trial within 72 hours of being admitted to hospital - People who are able to give written consent to partic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06600126 · University of Pennsylvania Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: **Patients:** - People who are 18 years of age or older - People who have a confirmed COPD diagnosis, supported by breathing tests or imaging scans showing lung changes - People who score 8 or higher on a standard depression symptom questionnaire (called the PHQ-8) at the start of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06614959 · McGill University Health Centre/Research Institute of the McGill Unive... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇦 CA

**Who might be able to join this trial:** - People aged 40 years or older - People who currently smoke or used to smoke, with a history of at least 10 pack-years of cigarette smoking (this is a measure of how much a person has smoked over time — confirm with trial site if unsure how this applies) - People who have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06615050 · Incyte Corporation Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 17 January 2031
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of joining the trial. - People who are planning to receive a stem cell transplant from a donor (called an allogeneic transplant) for one of the following blood cancers: certain types of acute or chronic leukemia with very f...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06619561 · Deciphera Pharmaceuticals, LLC Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2029
🇺🇸 US

Who might be able to join this trial: - People who have received a stem cell transplant from a donor and developed moderate to severe chronic graft-versus-host disease (cGVHD) — a condition where the donor cells attack the recipient's body — that requires treatment with immune-suppressing medicines. - People who have b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06629675 · University of Leicester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 September 2025
🇬🇧 GB

**Who might be able to join this trial:** - People who are willing and able to give their informed consent to take part in the study - People who have been referred for pulmonary rehabilitation (a structured breathing and exercise programme) at University Hospital Limerick (UHL) - People who have a confirmed diagnosis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06634810 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - People aged 40 years or older - People who have been diagnosed with COPD, recorded in their medical file, and whose condition falls into GOLD category B or E — these categories are based on symptom scores and how often flare-ups (exacerbations) have occurred, with or without a ho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06644898 · Acibadem University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with COPD, classified in groups A, B, or E according to the GOLD assessment system - People who are able to walk and move around on their own - People who have no medical reasons preventing them from doing exercise Who may not be able to join: - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06648733 · University Hospital Muenster Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with a serious, advanced illness such as late-stage cancer or severe chronic lung disease - People whose illness is at an advanced stage and whose life expectancy is estimated to be around 12 months or less - People who are already receiving ongoing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06652204 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - You must be a caregiver for a family member who has been diagnosed with COPD (a chronic lung disease). - You must be 18 years old or older. - The person you care for must currently be in a stable condition, meaning they have not had a flare-up or worsening of their COPD in th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06653413 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** **For people with COPD:** - Adults aged 30 to 80 years old who have been diagnosed with COPD according to 2023 international guidelines, confirmed by a breathing test showing reduced airflow even after using a bronchodilator (airway-opening) medication - People whose COPD rang...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06656299 · Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - Adults between 18 and 65 years old who are scheduled for a planned (non-emergency) gallbladder removal surgery using keyhole (laparoscopic) techniques under general anaesthesia - People who have been assessed by an anaesthesiologist as being in generally good to moderate over...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06660355 · H. Lee Moffitt Cancer Center and Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People who have a performance status score of 60% or higher on the Karnofsky scale, which means they are able to care for themselves and carry out some normal activities (confirm with trial site). - People who have been diagnosed with chronic graft-vers...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06663722 · University of Miami Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 5 May 2030
🇺🇸 US

**Who might be able to join this trial:** - You have received a stem cell (bone marrow) transplant from a donor (not your own cells) - You are aged 12 or older - You have been diagnosed with chronic Graft-versus-Host Disease (cGVHD) — a condition where the donor cells attack your body — and need a new treatment after...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06678191 · Chiesi Hungary Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇭🇺 HU

**Who might be able to join this trial:** - You have been diagnosed with asthma by a doctor (following standard medical guidelines) and have been receiving treatment for it for at least 3 years - You are 18 years of age or older and receive your asthma care on an outpatient basis (not in a hospital) - Your asthma is n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06682832 · Hacettepe University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
Turkey (Türkiye)

**Who might be able to join this trial:** This trial has three separate groups. Criteria differ depending on which group a person may belong to: **PRISm group (a specific lung function pattern):** - People who are older than 40 years of age - People who have been diagnosed with PRISm (a specific pattern seen on breat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06690385 · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 November 2024
🇪🇸 ES

Who might be able to join this trial: - People who currently smoke or used to smoke, with a significant smoking history of more than 30 pack-years (a measure of how much someone has smoked over their lifetime), including former smokers who quit more than 15 years ago - People who have been diagnosed with a lung conditi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06702696 · Amasya University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2025
Turkey (Türkiye)

Who might be able to join this trial: - You are between 50 and 80 years old - You have been diagnosed with COPD (a lung condition) - You do not follow a vegetarian or vegan diet - You are willing to eat the aronia berry (also called black chokeberry) provided by the trial - You are a non-smoker - You are willing to sig...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06703359 · ADIR Association Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇫🇷 FR

Who might be able to join this trial: - People who are over 18 years old - People who are covered by a social security scheme - People who have been diagnosed with COPD (chronic obstructive pulmonary disease), at any stage - People who have been referred to a pulmonary rehabilitation program - People who have completed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06707649 · Kirsehir Ahi Evran Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with COPD (a long-term lung condition) for at least 1 year - People whose COPD has been confirmed by breathing tests as being at a severe or very severe stage (known as GOLD stage III or IV) - People who are currently in hospital due to a sudden wor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06712563 · AstraZeneca Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 14 December 2026
🇨🇦 CA🇩🇪 DE🇬🇷 GR🇮🇹 IT🇯🇵 JP🇷🇴 RO🇬🇧 GB

Who might be able to join this trial: - You have moderate to severe COPD (a serious lung condition) and your doctor has recommended starting a specific triple inhaler treatment called BGF, following local prescribing guidelines - You are already taking part in a related single-arm study (a type of study where all parti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06713512 · Guy's and St Thomas' NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇬🇧 GB

**Who might be able to join this trial:** - Adults aged 18 years or older, of any gender - Women at any stage of menopause — pre-menopausal, peri-menopausal, or post-menopausal — are all eligible to take part - People who are willing and able to agree to take part by signing a consent form - Healthy participants who ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06717659 · Fu Jen Catholic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - People who are willing to sign a written consent form agreeing to take part. - People who have been diagnosed with pre-COPD or COPD (any stage from I to IV) based on the 2023 GOLD guidelines. - People who have been taking part in pulmonary rehabilitation therapy (a structured bre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06724848 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 October 2027
🇨🇳 CN

Who might be able to join this trial: - People who are able to sign an informed consent form agreeing to take part in the study. - People who are able to complete a specific breathing test (measuring how much air can be forced out of the lungs in one second) that meets recognised international standards. - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06726590 · Texas A&M University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are currently taking five or more medications, including prescription drugs, over-the-counter medicines, supplements, natural health products, cannabis products, or recreational drugs - People who are taking blood pressure or depression medications, even if the to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06732869 · Instituto Politécnico de Leiria Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇵🇹 PT

Who might be able to join this trial: - People who are over 40 years old - People who have been diagnosed with COPD (a lung condition affecting breathing) according to standard medical guidelines, and whose condition is currently stable, meaning no flare-ups in the past month - People who are already enrolled in a pulm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06733662 · Kahramanmaraş İstiklal University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 January 2025
Turkey (Türkiye)

Who might be able to join this trial: - People who have had a confirmed diagnosis of COPD (a chronic lung condition) for at least 6 months - People who are admitted to the chest clinic - People who have no communication difficulties - People who have voluntarily agreed to take part in the study Who may not be able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06735612 · Fundacio Privada Mon Clinic Barcelona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇪🇸 ES

Who might be able to join this trial: - People who are female or male - People who are 50 years of age or older - People with COPD who are seeking urgent medical care due to a sudden worsening of their condition, where symptoms such as shortness of breath, cough, and/or mucus have gotten worse over less than 14 days, p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06736145 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with moderate (Grade II) or severe (Grade III) COPD (a lung condition that makes breathing difficult) for at least one year. - People whose COPD is currently stable and not in an active flare-up. Who may not be able to join: - People who have any e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06749262 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇺🇸 US

**Who might be able to join this trial:** - You must be a Veteran (people of all genders, races, and ethnicities are welcome) - You must have breathing test results that show a specific pattern of airflow limitation (a ratio called FEV1/FVC below 0.7, and a lung capacity score between 30% and 80% of what is expected fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06751537 · LASARRUS Clinic and Research Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults between the ages of 21 and 100, of any sex or racial/ethnic background, who are able to read and sign consent forms in English or Spanish. - People who have been diagnosed with COPD (a chronic lung condition that makes breathing difficult) according to internationally...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06755008 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older (male or female). - A lung specialist has determined you need a bronchoscopy (a procedure to look inside the airways) for a reason such as follow-up care, investigating a lung nodule, coughing up blood, persistent cough, mucus production, rec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06756646 · National Cheng Kung University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇹🇼 TW

**Who might be able to join this trial:** - You have been diagnosed with COPD that has been rated as a moderate to very severe level (levels 2–4) - Your COPD has been stable, with no significant worsening, for at least the past three months - You have not taken part in any rehabilitation program in the last six months...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06772454 · Guangzhou Institute of Respiratory Disease Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been confirmed through tissue or cell testing to have a specific type of advanced lung cancer called squamous non-small cell lung cancer, at stage IIIB or IV - People who have been diagnosed with stable moderate to severe chronic obst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06772922 · University of Campinas, Brazil Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 November 2024
🇧🇷 BR

Who might be able to join this trial: - People who have been diagnosed with a chronic lung condition, such as COPD, pulmonary emphysema, pulmonary fibrosis, asthma, or another lung disease, and are being considered for a pulmonary (lung) rehabilitation program. - People who have been diagnosed with a heart condition —...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06776731 · Eastern Switzerland University of Applied Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇭 CH

**Who might be able to join this trial:** - People who have a confirmed diagnosis of COPD, shown through breathing tests (a specific ratio of less than 0.7 on lung function testing after using an inhaler) and a smoking history of more than 10 pack-years - People who are currently taking part in a pulmonary rehabilitat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06780046 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇧🇷 BR

**Who might be able to join this trial:** - People aged 18 or older (any sex) who have a confirmed diagnosis of COPD based on 2024 GOLD guidelines, which includes a history of exposure to risk factors (such as smoking) and breathing test results showing airflow limitation, along with a symptom score of 10 or higher on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06785337 · Beni-Suef University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2025
🇪🇬 EG

**Who might be able to join this trial:** - Adults aged 18 or older who have a flare-up of COPD (a lung disease that makes breathing difficult) along with breathing failure, and whose heart scan (echocardiogram) shows high blood pressure in the arteries of the lungs (with a specific pressure reading above 20 mmHg) **W...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06798077 · China-Japan Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇨🇳 CN

Who might be able to join this trial: - People aged 40 or older who have been diagnosed with chronic obstructive pulmonary disease (COPD), or people aged 18 or older who have been diagnosed with asthma or bronchiectasis. - People whose main reason for being admitted to hospital was a flare-up of COPD, asthma that was d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06802003 · McGill University Health Centre/Research Institute of the McGill Unive... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇦 CA

Who might be able to join this trial: - People aged 40 or older who currently smoke or used to smoke, with a smoking history of at least 10 pack-years (roughly 10 years of smoking one pack per day, or an equivalent amount) - People who have been diagnosed with moderate, severe, or very severe COPD, based on specific br...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06810323 · University of Virginia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with COPD (a chronic lung disease) - People whose lung function test results show a specific breathing pattern, where the ratio of two measurements (FEV1/FVC) is less than 0.80 after using a bronchodilator (a medication that opens the airways) - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06810622 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who are not pregnant - People who are not currently in prison or jail - People with advanced kidney disease where the kidneys are working at a reduced level, specifically with a kidney function score (eGFR) between 15 and 29 mL/min/1.73m² **W...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06822504 · IRCCS San Raffaele Roma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who are over 40 years of age, of any sex - People with a body mass index (a measure of body weight relative to height) above 18.5 - People who have been diagnosed with Chronic Obstructive Pulmonary Disease (COPD) — a long-term lung condition — and whose condition is cu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06825013 · Dr. J. Alberto Neder Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 January 2027
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with COPD (chronic obstructive pulmonary disease) - People aged 40 years or older, male or female - People who currently smoke or used to smoke, with a history of at least 20 pack-years (for example, one pack per day for 20 years, or two packs per d...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06841770 · Lineage Cell Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 10 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You have a traumatic spinal cord injury that is either fully affecting both movement and sensation, or affecting only movement but not sensation - Your spinal cord injury is located in a specific region of your neck or mid-back (between levels C-4 and T-10) (confirm with tri...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06843408 · Incyte Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are at least 12 years old at the time of signing the consent form. - People who are able to understand and are willing to sign a written consent form; for those aged 12 to 17, a parent or guardian must also provide consent. - People of Chinese background who have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06847061 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2029
🇺🇸 US

Who might be able to join this trial: - People who are 40 years of age or older - People who have been diagnosed with COPD by a doctor - People who live in a rural area, as defined by Rural-Urban Commuting Area codes 4 through 10 (confirm with trial site if unsure about your area's classification) - People who have a b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06850961 · Western Norway University of Applied Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇳🇴 NO

Who might be able to join this trial: - People who have been clinically diagnosed with Chronic Obstructive Pulmonary Disease (COPD), a long-term lung condition that makes breathing difficult. - People who experience mucus-related problems (such as coughing up mucus) at least 3 times per week. - People who can speak and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06858748 · McMaster University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People with a moderate-to-severe asthma diagnosis confirmed by a lung specialist, with objective test results supporting the diagnosis (such as breathing tests showing reversibility or airway sensitivity) - People with a moderate-to-s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06882265 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
🇧🇷 BR

**Who might be able to join this trial:** - People who have been diagnosed with both COPD (a lung condition that blocks airflow) and ILD (a condition that causes scarring or inflammation in the lungs), confirmed by clinical assessment, imaging, or tissue testing, following recognised international guidelines - People a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06883305 · AstraZeneca Phase 3 · 18 countries Recruiting
Recruiting Phase 3 Est. completion 13 March 2029
🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇿 CZ🇩🇰 DK🇩🇪 DE🇮🇳 IN +10 more

**Who might be able to join this trial:** - People aged 40 to 80 years old - People who have been diagnosed with COPD for at least 1 year - People whose lung function test results fall within a specific range at the screening visit (confirm with trial site for exact values) - People who have been taking either triple...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06888557 · Hong Kong Metropolitan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
Hong Kong

**Who might be able to join this trial:** - People aged 40 years or older - People who have a confirmed diagnosis of COPD (a chronic lung condition) - People who have had a COPD flare-up in the past 6 months that required a hospital stay, medical treatment, or a visit to a doctor - People who a doctor and the trial tea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06890767 · David Ruttens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇧🇪 BE

Who might be able to join this trial: - You must be willing and able to sign and date a consent form agreeing to take part in the study - You must be 18 years of age or older - You must have already been diagnosed with COPD (a long-term lung condition) - You must be able to speak and understand Dutch - You must need to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06892210 · Copenhagen Respiratory Research Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2030
🇩🇰 DK

Who might be able to join this trial: - You are 40 years old or older - You have been diagnosed with a flare-up (sudden worsening) of chronic obstructive pulmonary disease (COPD), recorded under the medical code ICDJ44 Who may not be able to join: - You have a condition that requires treatment with a specific type of...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06897410 · Corporació de Salut del Maresme i la Selva Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇪🇸 ES

Who might be able to join this trial: - People who are admitted to specific hospital units, including General Observation Units, Internal Medicine wards, or a Hospital at Home program - People who are 65 years of age or older - People whose hospital admission was caused by a worsening of a heart condition, a breathing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06897605 · Mansoura University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2025
🇪🇬 EG

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with moderate-to-advanced chronic kidney disease (stage 3 or 4) - People whose chronic kidney disease has caused anemia, with a hemoglobin (red blood cell) level below 11.5 g/dL - People who are currently being treated with medicati...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06915740 · Turku University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇫🇮 FI

Who might be able to join this trial: - People who are already taking part in a remote rehabilitation program designed for people with COPD (a lung condition affecting breathing) - People who have an official diagnosis of COPD recorded in their medical records - People whose doctors expect them to live for more than on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06921694 · University of Nottingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇬🇧 GB

**Who might be able to join this trial:** - People aged between 18 and 45 years old - People who are willing and able to give their informed consent to take part in the study - People who have had ongoing lower back pain (not caused by a specific known condition) for more than 3 months, in the area below the bottom of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06933758 · Temple University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇺🇸 US

Who might be able to join this trial: - People who are between 50 and 80 years old - People who have been screened for early lung cancer using a low-dose CT scan Who may not be able to join: - People who are younger than 50 or older than 80 years old - People who have not had a lung cancer screening Important: Always...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06948487 · Daewoong Pharmaceutical Co. LTD. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇰🇷 KR

Who might be able to join this trial: - You are between 19 and 75 years old at the time of signing the consent form - You are already scheduled by your doctor to take Fexuclu tablets (fexuprazan) for an approved medical reason - You have at least one symptom that your doctor has decided needs medical treatment - You ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06956742 · ADIR Association Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2028
🇫🇷 FR

Who might be able to join this trial: - Adults over 18 years of age - People who have been diagnosed with moderate to very severe COPD (classified as GOLD stage II, III, or IV) - People who have already completed a pulmonary rehabilitation program at the trial site - People whose 6-minute walk test result was less than...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06958666 · Sir Run Run Shaw Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with COPD (a chronic lung condition) according to the 2024 GOLD guidelines. - People whose lung function test results show an FEV1/FVC ratio below 60% (a specific measurement of how well air flows out of the lungs). - People with stable COPD wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06959095 · GlaxoSmithKline Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 20 August 2029
🇨🇳 CN🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - You are between 40 and 80 years old (inclusive) at the time of signing the consent form. - You have a higher-than-normal level of a type of white blood cell called eosinophils in your blood. - You have been diagnosed with moderate to severe COPD (chronic obstructive pulmonar...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06966271 · Tradeflex Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇭🇺 HU

Who might be able to join this trial: - People who have been diagnosed with an obstructive lung disease (such as asthma or COPD) by a lung specialist. - People who are able to use an inhaler device correctly after receiving training. - People who have had a standard breathing (lung function) test done during a regular...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06967324 · Copenhagen University Hospital, Hvidovre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇰 DK

Who might be able to join this trial: - People who have been diagnosed with COPD (a long-term lung condition that makes breathing difficult) - People who have had a flare-up (worsening of symptoms) of their COPD at least once in the past year - People who live in Høje Taastrup or Copenhagen - People who are cognitively...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06974981 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson Universi... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 50 and 80 years old - You are a current or former smoker with at least 20 "pack-years" of smoking history (for example, one pack per day for 20 years, or two packs per day for 10 years) - You are willing to take part in an observational study and be contacted...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06983366 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇪🇬 EG

Who might be able to join this trial: - Adults aged 18 years or older. - People who have been diagnosed with one of the specific lung conditions listed by the trial, or healthy individuals participating as a control comparison. - People who are able to give written consent to participate. Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06994689 · Groupe Hospitalier du Havre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with COPD (Chronic Obstructive Pulmonary Disease) - People who are over 18 years of age - People who are starting a pulmonary rehabilitation programme (a structured exercise and education programme for lung conditions) Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07000604 · Çankırı Karatekin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with COPD (a lung condition) for at least 6 months - Both people receiving care as hospital inpatients and those attending as outpatients may be considered - People who have given their agreement to take part in the research - People who are 18 year...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07002944 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇪🇬 EG

Who might be able to join this trial: - Adults between 18 and 65 years of age - People rated as physical status category II or III by an anaesthesiologist, meaning they have mild to moderate health conditions (confirm with trial site) - People who have shoulder pain following a mastectomy (breast removal surgery) - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07008170 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2026
🇪🇬 EG

**Who might be able to join this trial:** - You have stones in your gallbladder AND in the main bile duct (the tube that carries bile from the liver to the small intestine), confirmed by a scan. - You have been diagnosed with a gallbladder or bile duct infection, yellowing of the skin/eyes (jaundice), or test results...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07011810 · Fred Hutchinson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to understand the study information and are willing to sign a consent form agreeing to take part - You have previously received a stem cell transplant from a donor and have been diagnosed with active chronic graft-versus-host d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07012304 · Yujun DONG Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older who have voluntarily agreed to participate by signing a consent form - People who have previously received a stem cell transplant from a donor (using bone marrow, blood stem cells, or umbilical cord blood), using any of the standard transplant prepara...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07016412 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Je... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 5 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Male participants who agree to use contraception or abstinence, and to avoid donating semen during the study and for at least 30 days after it ends - Female participants who are not pregnant or breastfeeding, and who either are not able to become pregnant, or who agree to us...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07027852 · Women's College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇦 CA

**Who might be able to join this trial:** - You must be able to understand and agree to take part in the study on your own (have the mental capacity to give consent) - You must be willing to sign and date a consent form agreeing to take part - You must be willing to follow all of the study's procedures and requirements...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07030881 · First Affiliated Hospital of Ningbo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 65 years of age or older (any gender) - You have been diagnosed with either COPD (a lung condition affecting breathing) or asthma, confirmed by a doctor using standard guidelines - You are currently using a specific type of inhaler that combines three medicines in one...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07031336 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 May 2026
🇺🇸 US

Who might be able to join this trial: - You must already be a participant in the Duke-COPDGene Phase 4 study - You must be willing to give your consent to take part in this study Who may not be able to join: - If you are not already enrolled in the Duke-COPDGene Phase 4 study, you would not be eligible to join this tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07033260 · First Affiliated Hospital of Wannan Medical College Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 80 years of age - People who have been diagnosed with kidney failure (also called end-stage renal disease) - People who have been receiving regular dialysis treatments for more than three months - People who are willing and able to agree to take part and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07037836 · Bastiaan Driehuys Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 40 years old or older and are being seen as an outpatient (not currently admitted to a hospital) - You have chronic bronchitis, meaning you have had a mucus-producing cough for more than 3 months within a 2-year period - You are a current or former smoker with at leas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07039669 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are able to understand the study requirements and are willing to sign a consent form before taking part - You are between 40 and 85 years old - You are a current or former smoker with at least 10 "pack-years" of smoking history (for example, smoking one pack a day for 10...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07045155 · Chinese PLA General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old, of any gender - People who weigh at least 40 kg and have a body mass index (BMI) of 18 or above - People who have been receiving kidney dialysis (either hemodialysis or peritoneal dialysis) for at least 3 months before joining - People who hav...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07045532 · Shanghai Chest Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who are older than 18 years of age - People who have lung nodules that have been identified on a chest CT scan, confirmed as cancerous through a tissue test, and are planned to receive a treatment that destroys the nodule from outside the body (such as radiofrequency, micr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07050823 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇧🇷 BR

Who might be able to join this trial: - People who attend primary health care services in Brazil. - People who have been diagnosed with one or more existing, ongoing (non-respiratory) long-term health conditions, such as heart disease, diabetes, or high blood pressure. Who may not be able to join: - People whose healt...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07052396 · Sanofi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇩🇪 DE

**Who might be able to join this trial:** - You must be willing and able to give your agreement (consent) for your anonymised health information to be used in this study. - You must be an adult (18 years of age or older). - You have COPD that is not well controlled, even though you are already using a combination of lo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07059091 · Johns Hopkins University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2031
🇺🇸 US

Who might be able to join this trial: - People who are able and willing to give written consent to participate. - People who are older than 40 years of age at the time of screening. - People who have smoked cigarettes heavily enough to have accumulated more than 10 pack-years of smoking history. - People who have been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07059637 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You were admitted to the hospital mainly because of a COPD flare-up, or you were admitted for serious breathing problems with a COPD flare-up also present. - You had a CT scan (a type of detailed X-ray) during your hospital stay, and the scan showed that you have lower than n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07063563 · Eastern Switzerland University of Applied Sciences Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
Kyrgyzstan🇨🇭 CH

**Who might be able to join this trial:** - Adults aged 18 or older - People whose condition has been stable for more than 3 weeks, meaning no recent flare-ups or worsening episodes - People whose blood oxygen level is 88% or above while resting, but who experience a meaningful drop in oxygen levels during a standard 6...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07068438 · Suzhou Hengruihongyuan Medical Technology Co. LTD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are aged between 35 and 80 years old. - People who have chronic bronchitis, meaning they have had a mucus-producing cough for at least three months a year, for two years in a row, and other causes of that cough have been ruled out. - People whose symptom burden sc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07073950 · AstraZeneca Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 31 May 2027
🇩🇪 DE🇬🇧 GB

Who might be able to join this trial: - People who currently smoke or used to smoke, with a history of at least 10 pack-years of tobacco use (this means, for example, smoking one pack per day for 10 years, or two packs per day for 5 years). - People who have been diagnosed with COPD, confirmed by a specific breathing t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07085975 · McMaster University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2026
🇨🇦 CA

**Who might be able to join this trial:** This trial has two phases, each open to different groups of people. **Phase 1 – Healthy adults:** - Adults aged 18 or older who are in good health, with normal lung function test (spirometry) results and no history of chronic cough or other breathing conditions. **Phase 2 –...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07086339 · Pulmair Medical, Inc. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇫🇷 FR🇳🇱 NL

**Who might be able to join this trial:** - People who have signed an informed consent form agreeing to take part - People who have been diagnosed with COPD or emphysema - People who are at least 22 years old - People whose body mass index (a measure of height and weight) falls between 18 and 32 - People who can walk...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07090460 · Centre Hospitalier de la côte Basque Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇫🇷 FR

Who might be able to join this trial: - People who are over 18 years old and are currently admitted to an intensive care unit (ICU) - People who have a moderate or severe chronic lung condition (specifically classified as GOLD stage 3 or 4) - People who have a build-up of too much acid in the blood due to breathing dif...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07108166 · Philip Morris Products S.A. Not Applicable · 9 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇧🇬 BG🇨🇿 CZ🇩🇪 DE🇯🇵 JP🇵🇱 PL🇷🇴 RO🇸🇰 SK🇬🇧 GB +1 more

**Who might be able to join this trial:** - Adults of any sex aged 40 years or older. - People who have read, understood, and signed the required consent form that has been approved by an ethics committee. - People with a body mass index (a measure of body weight relative to height) between 17.6 and 40.0, and a body w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07112235 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇬🇧 GB

Who might be able to join this trial: **If you have COPD:** - You are a man or woman aged between 40 and 75 years old - You have been diagnosed with COPD or have a medical history of it - You have smoked at least 20 pack years (roughly 1 pack a day for 20 years, or equivalent), and use of e-cigarettes/vapes is also al...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07116915 · Guangdong Hengrui Pharmaceutical Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** **For all participants:** - Consent to take part in the trial has been given - Body weight is at least 45 kg and BMI is between 18 and 33 kg/m² - Heart tracing (ECG) results are normal, or only show minor changes that are not considered medically significant - Strict contracep...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07118306 · Viz.ai, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - People who are 40 years of age or older when they arrive at the emergency department. - People who have been clinically diagnosed with COPD and are visiting the emergency department due to a moderate or severe COPD flare-up. - A moderate flare-up means a sudden worsening of COPD...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07119229 · Pulmair Medical, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with COPD or emphysema - People who are at least 22 years old - People with a body mass index (BMI) between 18 and 32 - People who are able to walk between 100 and 400 metres in a 6-minute walk test at the baseline exam - People whose condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07122544 · University School of Physical Education, Krakow, Poland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇵🇱 PL

**Who might be able to join this trial:** - People who have been diagnosed with COPD (chronic obstructive pulmonary disease) by a lung specialist, confirmed using 2025 GOLD guidelines. - People whose lung function test results show that the airways are not severely restricted (FEV1 at or above 30% of the expected value...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07123909 · Botkin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇷🇺 RU

Who might be able to join this trial: - Adults aged 18 years or older - People who are currently receiving hemodialysis (a kidney filtering treatment) three times per week, with each session lasting at least 4 hours - People whose dialysis is working well enough, as measured by a specific test called KT/V, with a score...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07124078 · Incyte Corporation Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 31 January 2029
🇧🇪 BE🇩🇪 DE🇮🇹 IT🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - Children and teenagers aged 2 years old up to (but not including) 18 years old at the time of signing the consent forms. - People who have active, moderate to severe chronic graft-versus-host disease (a condition that can occur after a stem cell transplant) that requires treatmen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07125053 · Rush University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇺🇸 US

**Who might be able to join this trial:** - People who live in the continental United States - People aged 40 years or older - People who have been told by a doctor that they have COPD - People who were admitted to a hospital for a COPD-related reason at least once in the past 12 months - People who use an inhaled medi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07125352 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇪🇬 EG

Who might be able to join this trial: - Adults aged 18 or older - People who are being admitted to the Chest Department at Ain-Shams University Hospitals - People who have been diagnosed with a sudden worsening of a long-term lung condition called COPD (Chronic Obstructive Pulmonary Disease), confirmed using internatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07131020 · Henan University of Traditional Chinese Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stable chronic obstructive pulmonary disease (a long-term lung condition, often called COPD) - People whose condition matches certain Traditional Chinese Medicine (TCM) patterns related to weakness in the lungs, lungs and spleen, or lungs a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07135427 · University of Alabama at Birmingham Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - Adults who carry one copy of a specific genetic variant called the SERPINA1 Z allele (a gene change linked to a condition called Alpha-1 Antitrypsin Deficiency) - People who have either had no serious flare-ups of a chronic lung condition (COPD) in the past year, or who have had...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07135583 · Thomas Jefferson University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2027
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 70 years of age - People who have had a spinal cord injury (SCI) for at least 1 year, with the injury located at or below a specific level of the spine (between the third cervical and eighth thoracic vertebrae) - People with an incomplete spinal cord injury,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07140328 · Haisco Pharmaceutical Group Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 40 to 80 years old (any gender) at the first screening visit - People who have been diagnosed with chronic obstructive pulmonary disease (COPD) according to 2025 GOLD diagnostic standards, with symptoms consistent with COPD for at least 1 year — this includes ong...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07146698 · Benha University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
🇪🇬 EG

Who might be able to join this trial: - Adults aged 18 years or older, of any sex - People who have been diagnosed with COPD (a chronic lung condition), confirmed by a specific breathing test result (post-bronchodilator FEV1/FVC below 70%) - People who are currently being followed up through the relevant outpatient cli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07160322 · Seoul National University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with chronic obstructive pulmonary disease (COPD) based on 2025 international COPD guidelines (GOLD criteria) - People with known risk factors for COPD, such as a history of smoking, exposure to harmful substances at work, or a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07177339 · GlaxoSmithKline Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 2 November 2029
🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - Men, or women who meet specific eligibility criteria set by the trial site - People who have a higher-than-normal level of a type of white blood cell called eosinophils, measured through a blood test - People who have been diagnosed with moderate to severe COPD for at least...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07183657 · Charles University, Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇿 CZ

**Who might be able to join this trial:** **Patients:** - People aged 18 or older - People who have previously been diagnosed with asthma or chronic obstructive pulmonary disease (COPD), confirmed using recognised international diagnostic guidelines - People who are able to cooperate and participate in the trial - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07185178 · Istinye University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 August 2025
Turkey (Türkiye)

Who might be able to join this trial: - People aged between 40 and 80 years - People who have been diagnosed with Asthma-COPD Overlap Syndrome (ACOS), which is a condition involving features of both asthma and chronic obstructive pulmonary disease - People who score 23 or higher on the Nijmegen Questionnaire, a tool us...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07185659 · Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

Who might be able to join this trial: - People who have been admitted to hospital and diagnosed with a lung condition called Chronic Obstructive Pulmonary Disease (COPD), confirmed using internationally recognised guidelines - People aged 40 years or older - People whose breathing test results show a specific pattern o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07190209 · Sanofi Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 27 November 2029
🇦🇷 AR🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇬🇪 GE🇯🇵 JP🇸🇦 SA +3 more

Who might be able to join this trial: - People who are between 40 and 80 years old - People who have been diagnosed with chronic obstructive pulmonary disease (COPD) by a doctor for at least 1 year - People whose breathing test results fall within a specific range that indicates moderate-to-severe COPD (confirm with tr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07195838 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2027
Hong Kong

**Who might be able to join this trial:** - People aged between 50 and 80 years old - Men or women are eligible - People who have completed at least a primary school level of education - People who have been diagnosed with COPD, confirmed by specific breathing test results showing reduced lung function (confirm with t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07199361 · Florida International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 January 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with long-term (chronic) pain in a specific part of the body (peripheral pain) that was caused by an injury or surgery. - People between the ages of 19 and 80 years old. - People who are currently taking medication to manage their pain. - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07212439 · Clinica Universidad de Navarra, Universidad de Navarra Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇪🇸 ES

Who might be able to join this trial: - People who are 18 years of age or older. - People who have already been diagnosed with COPD. - For the inpatient group: people who are currently in hospital and have been assessed as having a moderate or severe COPD flare-up. - For the outpatient group: people who have had at lea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07213128 · KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇧🇪 BE

**Who might be able to join this trial:** - People who have been admitted to hospital for at least 3 days due to a sudden worsening of COPD symptoms - People who can read and speak French, Dutch, or English - People aged 35 years or older - People who are able to give their informed agreement to participate in the tri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07214844 · Montefiore Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of screening - People whose main problem is lower back pain that appears to be coming from the small joints along the spine (called facet joints), affecting both sides of the back, based on physical examination findings - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07222410 · Fisher and Paykel Healthcare Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

Who might be able to join this trial: - You are mentally able to understand and agree to take part in the trial yourself - You are 22 years of age or older - You are currently in hospital with low oxygen levels or difficulty breathing - You have been diagnosed with COPD (a lung condition that makes it hard to breathe)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07245576 · AstraZeneca Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇦🇷 AR🇪🇬 EG🇲🇽 MX🇸🇦 SA🇹🇼 TW🇦🇪 AE🇻🇳 VN

**Who might be able to join this trial:** *For the suspected asthma group:* - People aged 18 or older (or the legal age of consent in the country where the study is taking place) who have not yet been formally diagnosed with asthma - People experiencing symptoms such as wheezing, coughing, chest tightness, or shortnes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07249567 · Karabuk University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 September 2026
Turkey (Türkiye)

**Who might be able to join this trial:** This trial has three separate groups. People may be considered for one of the following groups: **COPD Group:** - People who are older than 40 years of age - People who have been diagnosed with COPD (a chronic lung condition) - People whose COPD is currently in a stable condi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07259174 · Isala Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇳🇱 NL

Who might be able to join this trial: - People who are currently in hospital mainly because of a severe flare-up of COPD (a serious lung condition) - People who have had a breathing test (called spirometry) within the last 5 years that showed results consistent with COPD (confirm with trial site for exact values) - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07267104 · Corporacion Parc Tauli Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 April 2025
🇪🇸 ES

**Who might be able to join this trial:** - You are between 40 and 80 years old. - You have been diagnosed with COPD (a lung condition) confirmed by breathing tests. - You have been using a breathing support machine at home (called NIV therapy) for at least 6 months, and you use it for more than 5 hours every day. - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07267130 · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to join voluntarily and sign a consent form after being fully informed about the study - Healthy adults between 18 and 55 years old (inclusive), of any gender - Men who weigh at least 50kg and women who weigh at least 45kg, with a body mass index (BMI) betw...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07285642 · Saglik Bilimleri Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
Turkey (Türkiye)

Who might be able to join this trial: - People between 40 and 70 years of age - People who have been diagnosed with moderate-to-severe COPD (classified as GOLD stage II or III) - People whose COPD has been stable, meaning no flare-ups or worsening of symptoms in the past 4 weeks - People with a body mass index (BMI) be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07288554 · Bambusa Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years (for the healthy volunteer part) or 35 to 75 years (for the patient part), with a body weight no higher than 120 kg and a body mass index between 18 and 32 - Women of childbearing potential who have a negative pregnancy test result - People who do...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07292714 · Mabwell (Shanghai) Bioscience Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are between 40 and 75 years old (inclusive) - People who have been diagnosed with COPD by a doctor for at least 1 year before the screening visit - People who have had at least 2 moderate COPD flare-ups, or at least 1 severe COPD flare-up, in the 12 months before the s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07293429 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 February 2026
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with Stage 1 or Stage 2 COPD (chronic obstructive pulmonary disease) - People whose COPD is accompanied by a "forward head posture," meaning the head sits noticeably further forward than normal - People whose craniovertebral angle (a measurement of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07297303 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇹🇼 TW

Who might be able to join this trial: - Adults over 18 years of age - People who are scheduled to receive their first-ever bone marrow or stem cell transplant from a donor (known as an allogeneic transplant) Who may not be able to join: - People who are experiencing respiratory failure (serious breathing problems wher...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07302425 · Istituti Clinici Scientifici Maugeri SpA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with COPD (a lung condition) confirmed by a specific breathing test result (FEV1/FVC below 70%), following recognised medical guidelines - People whose condition is currently stable, based on a blood measurement showing the body's acid-balance i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07307781 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 June 2027
🇷🇺 RU

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of joining the study - People who have signed and dated a consent form agreeing to take part, in line with the study's legal and ethical requirements - People with a confirmed diagnosis of moderate-to-very severe COPD (class...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07315958 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who are 40 years of age or older. - People with a smoking history of 10 pack-years or more (this means smoking roughly one pack of cigarettes per day for 10 years, or an equivalent amount over a different time period — confirm with trial site if unsure). - People who are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07344649 · Saglik Bilimleri Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with COPD (a lung condition affecting breathing) confirmed using standard medical guidelines known as GOLD criteria - People whose COPD has been stable, meaning no serious flare-ups or hospital stays in the past 4...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07349524 · Reistone Biopharma Company Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have freely chosen to sign a written consent form agreeing to take part - People aged between 40 and 80 years old, of any gender - People with a body mass index (a measure of body weight relative to height) of 18 or above - People who have been formally diagnosed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07351734 · Joincare Pharmaceutical Group Industry Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇨🇳 CN

Who might be able to join this trial: - Adults who have been formally diagnosed with COPD, with medical records that support this diagnosis according to standard guidelines - People whose history includes known causes of COPD, such as a history of smoking - People who are already on a stable, guideline-recommended trea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07353034 · Medical University of South Carolina Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 April 2026
🇺🇸 US

Who might be able to join this trial: - People who are 40 years of age or older - People who have been told by a doctor that they have COPD, or who are currently being treated for COPD - People who speak English - People who have access to the internet Who may not be able to join: - People who have a history of psycho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07355868 · Regend Therapeutics Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 15 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 40 and 80 years old (both ages included), and any gender may apply - You have been diagnosed with COPD (a lung condition) according to the 2025 international COPD guidelines - During a screening walking test, you are able to walk at least 150 metres but less t...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07363694 · Pfizer Phase 3 · 8 countries Recruiting
Recruiting Phase 3 Est. completion 24 October 2030
🇦🇷 AR🇨🇦 CA🇨🇳 CN🇮🇳 IN🇯🇵 JP🇰🇷 KR🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with chronic obstructive pulmonary disease (COPD) for at least 12 months, based on recognised international guidelines. - People whose lung function test results show a specific level of airflow limitation — moderate to moderately severe (confi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07375433 · National Medical Research Center for Therapy and Preventive Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇷🇺 RU

Who might be able to join this trial: - You have been officially diagnosed with COPD (a long-term lung condition that makes it hard to breathe) - You are currently in hospital being treated for COPD - You are a citizen of the Russian Federation - You are between 50 and 70 years old - You are willing to give your consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07380711 · Sanofi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 August 2030
🇫🇷 FR

Who might be able to join this trial: - People who are willing and able to give consent for their anonymised health information to be used in this study. - People who are adults (18 years of age or older). - People who have Chronic Obstructive Pulmonary Disease (COPD) — a long-term lung condition — that is not well con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07382258 · Novlead Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇨🇳 CN

Who might be able to join this trial: - You are between 40 and 75 years old (inclusive). - You have a history of smoking totalling at least 10 "pack-years" (for example, 1 pack per day for 10 years, or similar), and you have stopped smoking for at least one month before joining the study. - You have been diagnosed with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07383896 · Thammasat University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇹🇭 TH

Who might be able to join this trial: - People who are 18 years of age or older Who may not be able to join: - People who are unable to perform a spirometry test (a breathing test that measures how much air the lungs can hold and how fast air can be breathed out) Important: Always verify eligibility with the trial si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07394712 · Institut de Recerca Biomèdica de Lleida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇪🇸 ES

**Who might be able to join this trial:** - You are between 40 and 75 years old. - You have been officially diagnosed with moderate to severe chronic obstructive pulmonary disease (COPD), a long-term lung condition that makes breathing difficult. - Your condition has been stable for at least 4 weeks since your last ser...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07406048 · Chiesi Farmaceutica Ltda. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇧🇷 BR

Who might be able to join this trial: - People who are 40 years of age or older at the time they started taking the medication BDP/FF/GB (a combination inhaler also known as Trimbow®) - People who have a documented diagnosis of severe or very severe COPD before starting BDP/FF/GB - People who had a COPD symptom score (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07406659 · University of Yalova Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with COPD (chronic obstructive pulmonary disease) according to standard medical guidelines known as the GOLD criteria - People who have not had a sudden worsening of their COPD symptoms (called an acute exacerbation) in the past month - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07418736 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇨🇳 CN

Who might be able to join this trial: - People who understand the study and are willing to sign a consent form agreeing to take part. - People aged 40 to 85 years old (male or female) at the time of signing the consent form. - People who weigh at least 40 kg. - People who have been diagnosed with COPD for at least 12 m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07434869 · Brian Keller Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2030
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older, or children and teenagers aged 7 to 17, who have received a single or double lung transplant - People who have been diagnosed with a lung transplant complication called CLAD (at any stage) and have been prescribed a treatment called ECP therapy - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07441226 · RSUP Persahabatan Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇮🇩 ID

**Who might be able to join this trial:** - Adults between the ages of 40 and 75 years. - People who have been diagnosed with a specific severity of Chronic Obstructive Pulmonary Disease (COPD), classified as "Group E" under international guidelines from 2023. - People who have been using a combination of three inhale...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07447232 · Fu Jen Catholic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇹🇼 TW

Who might be able to join this trial: - You are between 18 and 80 years old - You have been diagnosed with a long-term breathing or lung condition, such as COPD, asthma, bronchiectasis, or interstitial lung disease - You are willing to learn and follow the instructions for using a special breathing measurement device c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07460154 · Northumbria Healthcare NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 March 2029
🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with COPD (a chronic lung condition), with this diagnosis recorded in their GP records for at least 12 months - People aged 35 years or older - People who have been prescribed prednisolone (a steroid medication) 3 or more times in the past 12 months...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07460999 · Zealand University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇩🇰 DK

Who might be able to join this trial: - People who have had surgery to remove early-stage (stage I) lung cancer using a keyhole surgical technique (called VATS), where the surgery took place between 6 and 18 months ago - People who are still experiencing symptoms after their surgery, meaning at least one symptom has be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07462221 · Çanakkale Onsekiz Mart University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 March 2026
Turkey (Türkiye)

Who might be able to join this trial: - You must have been diagnosed with COPD (a lung condition) for at least 6 months. - You must be currently receiving treatment as an inpatient in an internal medicine or surgical ward. - You must be willing to sign a consent form agreeing to take part in the study. - You must have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07474220 · Fu Jen Catholic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with pre-COPD or COPD (a lung condition affecting breathing) at any stage, as defined by 2023 international lung disease guidelines - Healthy people who do not have any ongoing or serious medical conditions Who may not be able to join: - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07477600 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2029
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand the study plan and are willing to sign a written consent form agreeing to take part. - People aged between 40 and 80 years old, of any gender. - People who have been diagnosed with moderate to severe COPD (a serious lung condition affecting breat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07509606 · National Cheng Kung University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 May 2025
🇹🇼 TW

**For Healthy Individuals** Who might be able to join this trial: - People who have never tried whole-body vibration therapy before and have never worked in a job or played a sport that regularly exposes them to vibration. - People aged between 18 and 65 years. Who may not be able to join: - People who are pregnant....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07518446 · Amager Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇩🇰 DK

Who might be able to join this trial: - People who are 18 years of age or older. - People who have been referred to one of two specific psychiatric outpatient clinics (called FACT or OPUS) in the Capital Region of Denmark. - People who are beginning a new course of treatment at one of these outpatient clinics. - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07518472 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
🇵🇰 PK

Who might be able to join this trial: - People who are between 40 and 65 years old - Both men and women are eligible - People who experience breathlessness that falls within Grade 1 to 3 on a standard breathlessness rating scale (the mMRC scale) - People who have been diagnosed with mild COPD (chronic obstructive pulmo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07519603 · National Geriatric Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇻🇳 VN

Who might be able to join this trial: - People who are 60 years of age or older - People who have been diagnosed with a lung condition called COPD (Chronic Obstructive Pulmonary Disease), confirmed using standard medical guidelines known as the GOLD criteria - People whose COPD has been stable, meaning no serious flare...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07522008 · Azienda Ospedaliera Brotzu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 or older whose kidneys have failed completely and who are receiving regular dialysis treatment (the most advanced stage of chronic kidney disease). - People who have been on a stable, unchanged dialysis routine for at least 3 months before joining the trial. - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07531771 · Foundation University Islamabad Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2026
🇵🇰 PK

**Who might be able to join this trial:** - People who have been diagnosed with Grade I COPD, which is the mildest stage of this lung condition, where lung function testing shows results above 80% of what is considered normal - People between the ages of 40 and 65 years - Both men and women are eligible - People who ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07535008 · Fred Hutchinson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who are receiving or have received a specific type of stem cell transplant (called a T-replete allogeneic hematopoietic cell transplant) for any medical reason, including people who have had a previous transplant - People whose stem cell donor is...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07536256 · Waianae Coast Comprehensive Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇺🇸 US

Who might be able to join this trial: - You are between 12 and 25 years old - You live in the Wai'anae area with the zip code 96792 - You receive your healthcare at Waianae Coast Comprehensive Health Center (WCCHC), including any of their school-based health centers - A WCCHC healthcare provider has identified you as s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07552584 · Vejle Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇩🇰 DK

**Who might be able to join this trial:** - People who have been diagnosed with COPD (a chronic lung condition) - People who are 50 years of age or older - People who are current smokers or have smoked in the past - People who speak and understand Danish - People who are able to give their agreement to participate afte...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07567872 · Guangdong Hengrui Pharmaceutical Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who have given their written agreement to take part in the trial - People who weigh at least 45 kg and have a body mass index (BMI) between 18 and 33 - People whose heart rhythm test (ECG) results are normal or only slightly abnormal in a way that is not medically concerni...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07573098 · Björn Nordlund Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 May 2027
🇸🇪 SE

Who might be able to join this trial: - People aged 40 years or older who have been officially diagnosed with COPD (a lung condition) - People who are currently using at least two inhaled medications for their COPD (such as a combination inhaler, or several separate inhalers) - People who have had at least one COPD fla...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07574879 · Zagazig University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇪🇬 EG

Who might be able to join this trial: - Adults who are 40 years of age or older. - People who have been diagnosed with COPD (a lung condition), confirmed by a breathing test, and who have also tested positive for a stomach bacteria called H. pylori. - People who are willing to take part and agree to any required tests...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07579052 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇪🇬 EG

**Who might be able to join this trial:** - You are 40 years of age or older - You have been diagnosed with chronic obstructive pulmonary disease (COPD) — a long-term lung condition that makes it hard to breathe — either confirmed by a breathing test or based on your medical history - You are currently in the intensiv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07590362 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇪🇬 EG

Who might be able to join this trial: - People with COPD who are on a breathing machine (ventilator) and have been assessed by their medical team as ready to begin the process of coming off it. - People who have been on invasive mechanical ventilation for more than 24 hours before a breathing trial is attempted. - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07597031 · Matthias Wilhelm, MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇨🇭 CH

Who might be able to join this trial: - You must be 18 years old or older - You must be getting ready to leave an inpatient rehabilitation program at the Bern Rehab Center in Heiligenschwendi or the Insel Hospital, with no more than 10 days left before discharge - You must belong to one of these groups: people who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07602192 · Korea University Guro Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2027
🇰🇷 KR

Who might be able to join this trial: - People who are 19 years of age or older - People in the COPD group who have breathing test results showing a specific airflow limitation (a ratio called FEV1/FVC below 0.70, measured after using a bronchodilator inhaler) - People in the asthma group who have been formally diagnos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07605117 · Universidad Manuela Beltrán Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 July 2026
🇨🇴 CO

Who might be able to join this trial: - People between 50 and 80 years old who have been diagnosed with moderate or severe COPD (a long-term lung condition that makes breathing difficult) - People who have not had a sudden worsening of their COPD symptoms in the last 4 weeks - People who are physically able to take par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07606703 · WeiShi Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand the study and are willing to sign a written consent form - People aged between 14 and 65 years - People who have been diagnosed with a specific form of chronic graft-versus-host disease (a condition that can occur after a stem cell or bone marrow...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07610395 · Altesa Biosciences, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 November 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing to sign a consent form agreeing to take part in the study and allow their medical records to be shared if needed. - People aged 40 to 85 years old at the time of signing the consent form. - People who are sexually active or capable of having children (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07627763 · Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older. - Your COPD must be stable, meaning you have not had a flare-up that needed treatment in the last 4 weeks. - You must have a confirmed COPD diagnosis, shown by a specific breathing test result (confirm with trial site). Who may not be able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07635446 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇵🇰 PK

Who might be able to join this trial: - People of any gender (male or female) may be considered. - People between the ages of 40 and 60 years old. - People who have been diagnosed with COPD (a long-term lung condition that makes it hard to breathe). - People who are willing to take part in the trial. Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07646587 · Windward Bio Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 17 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults between the ages of 40 and 80 - People whose breathing test results (taken after using an inhaler) show a specific pattern of reduced lung function, measured within a certain range (confirm with trial site for exact values) - People who have been using a stable combin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07665931 · Azienda Socio Sanitaria Territoriale di Lodi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇮🇹 IT

Who might be able to join this trial: - People aged 18 or older - People who have been diagnosed with severe or very severe COPD (classified as GOLD stage 3 or 4) - People whose lungs show signs of being over-inflated (trapping too much air), confirmed by a specific breathing test called a nitrogen wash-out test, with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07684820 · Expedition Therapeutics, Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have given written agreement to take part in the study - People with a body mass index (BMI) between 18.5 and under 35, and who weigh at least 50 kg (males) or at least 45 kg (females) - People who have been diagnosed with COPD (a long-term lung condition) for at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07704567 · Minnesota HealthSolutions Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have previously been diagnosed with COPD or chronic interstitial lung disease - People who have been prescribed supplemental oxygen for use during physical activity for at least 1 month before joining the trial - People aged 25 years or older - People whose symptom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07707271 · George Papanicolaou Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇬🇷 GR

**Who might be able to join this trial:** - People who have been diagnosed with COPD based on their smoking history or exposure to other risk factors, confirmed by a specific breathing test result (post-bronchodilator FEV1/FVC ratio below 0.7) - People whose blood oxygen level at rest while breathing room air is above...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for COPD. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Lung Foundation Australia is the national body for COPD and the wider lung health community.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.